Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report) fell 4.5% on Friday . The company traded as low as $2.11 and last traded at $2.11. 13,670 shares traded hands during mid-day trading, a decline of 18% from the average session volume of 16,736 shares. The stock had previously closed at $2.21.
Alaunos Therapeutics Price Performance
The stock has a fifty day simple moving average of $2.68 and a two-hundred day simple moving average of $7.62.
Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share for the quarter.
Institutional Trading of Alaunos Therapeutics
Alaunos Therapeutics Company Profile
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Featured Stories
- Five stocks we like better than Alaunos Therapeutics
- 5 discounted opportunities for dividend growth investors
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- Airline Stocks – Top Airline Stocks to Buy Now
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Retail Stocks Investing, Explained
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.